# Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa

> **NCT04979520** · EARLY_PHASE1 · COMPLETED · sponsor: **Rockefeller University** · enrollment: 4 (actual)

## Conditions studied

- Hidradenitis Suppurativa
- Acne Inversa

## Interventions

- **DRUG:** Brodalumab

## Key facts

- **NCT ID:** NCT04979520
- **Lead sponsor:** Rockefeller University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-05
- **Primary completion:** 2022-07-25
- **Final completion:** 2022-07-25
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04979520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04979520, "Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04979520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*